Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious Covid-19 complications

Saint Luke's Mid America Heart Institute and drug company AstraZeneca PLC are conducting a clinical trial to see if a drug now used to treat diabetes could help prevent deadly complications in Covid-19 patients. The DARE-19 trial involves dapagliflozin, which is marketed in the United States as Farxiga and can reduce blood glucose levels in diabetes patients. The double-blind trial follows previous research indicating that the drug also may provide some protection to the heart and kidney for high-risk…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news